Labs and Groups
Addison Cancer Research Lab
Addison Cancer Research Lab
Team Leader
Christina Addison
Senior Scientist, Cancer ResearchWhat We Do
Our laboratory focuses on two main themes; 1) the role of the tumour extracellular matrix (ECM) microenvironment in modulating tumour growth and angiogenesis and 2) cancer biomarker discovery.
Research Activities
Current Research Projects
Our laboratory focuses on mechanisms driving tumor metastasis and identifying potential therapeutic strategies to inhibit metastatic tumor growth. We have a particular interest in understanding mechanisms driving metastatic growth in the bone, which is the most common site of metastasis for prostate, breast and lung cancers. We are also interested in understanding the role of miRNA in processes associated with tumor growth, in particular angiogenesis. Specific areas of ongoing research are:
1) Understanding the effects of conventional treatment on the metastatic tumor microenvironment and how this effects subsequent tumor growth.
2) Understanding the contributions of bone resident cells in maintaining dormancy of disseminated metastatic tumor cells or facilitating the ability of tumor cells to overcome microenvironment-induced dormancy.
3) Identifying metabolic vulnerabilities in metastatic tumors and evaluating whether their therapeutic targeting can prevent progressive metastatic growth or sensitize tumors to conventional therapy.
4) Evaluating whether metabolic vulnerabilities can be utilized for tumor diagnostic or prognostic predictions.
5) Understanding how miRNA regulate the angiogenic process and what role extracellular vesicle derived miRNA affect angiogenesis and tumor progression.
Keywords: angiogenesis, bone metastasis, tumour microenvironment, biomarkers, cancer therapy, signal transduction
https://orcid.org/0000-0002-3492-475X
Our laboratory focuses on mechanisms driving tumor metastasis and identifying potential therapeutic strategies to inhibit metastatic tumor growth. We have a particular interest in understanding mechanisms driving metastatic growth in the bone, which is the most common site of metastasis for prostate, breast and lung cancers. We are also interested in understanding the role of miRNA in processes associated with tumor growth, in particular angiogenesis. Specific areas of ongoing research are:
1) Understanding the effects of conventional treatment on the metastatic tumor microenvironment and how this effects subsequent tumor growth.
2) Understanding the contributions of bone resident cells in maintaining dormancy of disseminated metastatic tumor cells or facilitating the ability of tumor cells to overcome microenvironment-induced dormancy.
3) Identifying metabolic vulnerabilities in metastatic tumors and evaluating whether their therapeutic targeting can prevent progressive metastatic growth or sensitize tumors to conventional therapy.
4) Evaluating whether metabolic vulnerabilities can be utilized for tumor diagnostic or prognostic predictions.
5) Understanding how miRNA regulate the angiogenic process and what role extracellular vesicle derived miRNA affect angiogenesis and tumor progression.
Keywords: angiogenesis, bone metastasis, tumour microenvironment, biomarkers, cancer therapy, signal transduction
https://orcid.org/0000-0002-3492-475X
Selected Publications
1. Kirby A, Suchy M, Graf D, Calvert, ND, Charlton TA, Ben RN, Addison CL, Shuhendler A. 2024. It’s a trap! Aldolase-prescribed C4-deoxyfluorination affords intracellular trapping and the tracing of fructose metabolism by PET. J Nucl Med. 2024 Mar 1;65(3):475-480. doi: 10.2967/jnumed.123.266905
2. Zhao H, Pond G, Simos D, Wang Z, Robertson S, Singh G, Vandermeer L, Clemons M, Addison CL. 2023. Doxycycline-induced changes in circulating MMP or TIMP2 levels are not associated with skeletal-related event- free or overall survival in bone metastatic breast cancer patients. Cancers: Special issue “Invasion and Progression of Solid Tumors in Bone”. 15, 571. doi.org/10.3390/cancers15030571
3. *Allen V, Coulombe J, Zhao H, *Kreps LM, Cook DP, Pryce B, Clemons M, Vanderhyden BC, Gray DA, Addison CL. 2022. VIVA1: a more invasive subclone of MDA-MD-134VI invasive carcinoma cells with increased metastatic potential in xenograft models. Br J Cancer. 2022 Jul;127(1):56-68. doi:10.1038/s1416-022-01778-7. Epub 2022 Mar 22. PMID 35318435
4. *Gunn SA, *Kreps LM, Zhao H, Landon K, *Ilacqua JS, Addison CL. 2022. Focal adhesion kinase inhibitors prevent osteoblast mineralization in part due to suppression of Akt-mediated stabilization of osterix. J Bone Oncol. 2022 May 13;34”100432. Doi: 10.1016/j.jbo.2022.100432.ecollection 2022 Jun. PMID:35620245
5. Beltran-Bless AA, Murshed M, Zakikhani M, Kuchuk I, Bouganim N, Robertson S, Kekre N, Vandermeer L, Li J, Addison CL, Rauch F, Clemons M, Kremer R. 2021. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients. Bone Rep. 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. eCollection 2021 Dec.
6. Brun E, Calvert N, Suchý M, Kirby A, Melkus G, Garipov R, Addison CL, Shuhendler A. 2021. Mapping Vitamin B6 Metabolism by HydrazoCEST Magnetic Resonance Imaging. Chemical Communications (Camb).;Oct 19;57(83):10867-10870. doi: 10.1039/d1cc03704h
7. *Kreps L, Addison CL. 2021. Targeting intercellular communication in the bone microenvironment to prevent disseminated tumor cell escape from dormancy and bone metastatic tumor growth. Int J of Mol Sci. Mar 13;22(6):2911. doi: 10.3390/ijms22062911.
8. Sulaiman A, McGarry S, Chambers J, Al-Kadi E, Phan A, Li L, Mediratta K, Dimitroulakos J, Addison C, Li X, Wang L. 2020. Targeting hypoxia sensitizes TNBC to cisplatin and promotes inhibition of both bulk and cancer stem cells. Int J Mol Sci. Aug 12;21(16):5788. Doi 10.3390/ijms21165788.
9. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen C, Diamandis EP, Siu KWM, Marshall JG. 2019. The plasma peptides of breast versus ovarian cancer. Clin Proteomics. Dec 23;16:43. doi: 10.1186/s12014-019-9262-0. eCollection 2019.
10. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen CE, Diamandis EP, Michael Siu KW, Marshall JG. 2018. The plasma peptides of ovarian cancer. Clin Proteomics. Dec 21;15:41. doi: 10.1186/s12014-018-9215-z. eCollection 2018.
2. Zhao H, Pond G, Simos D, Wang Z, Robertson S, Singh G, Vandermeer L, Clemons M, Addison CL. 2023. Doxycycline-induced changes in circulating MMP or TIMP2 levels are not associated with skeletal-related event- free or overall survival in bone metastatic breast cancer patients. Cancers: Special issue “Invasion and Progression of Solid Tumors in Bone”. 15, 571. doi.org/10.3390/cancers15030571
3. *Allen V, Coulombe J, Zhao H, *Kreps LM, Cook DP, Pryce B, Clemons M, Vanderhyden BC, Gray DA, Addison CL. 2022. VIVA1: a more invasive subclone of MDA-MD-134VI invasive carcinoma cells with increased metastatic potential in xenograft models. Br J Cancer. 2022 Jul;127(1):56-68. doi:10.1038/s1416-022-01778-7. Epub 2022 Mar 22. PMID 35318435
4. *Gunn SA, *Kreps LM, Zhao H, Landon K, *Ilacqua JS, Addison CL. 2022. Focal adhesion kinase inhibitors prevent osteoblast mineralization in part due to suppression of Akt-mediated stabilization of osterix. J Bone Oncol. 2022 May 13;34”100432. Doi: 10.1016/j.jbo.2022.100432.ecollection 2022 Jun. PMID:35620245
5. Beltran-Bless AA, Murshed M, Zakikhani M, Kuchuk I, Bouganim N, Robertson S, Kekre N, Vandermeer L, Li J, Addison CL, Rauch F, Clemons M, Kremer R. 2021. Histomorphometric and microarchitectural analysis of bone in metastatic breast cancer patients. Bone Rep. 2021 Oct 22;15:101145. doi: 10.1016/j.bonr.2021.101145. eCollection 2021 Dec.
6. Brun E, Calvert N, Suchý M, Kirby A, Melkus G, Garipov R, Addison CL, Shuhendler A. 2021. Mapping Vitamin B6 Metabolism by HydrazoCEST Magnetic Resonance Imaging. Chemical Communications (Camb).;Oct 19;57(83):10867-10870. doi: 10.1039/d1cc03704h
7. *Kreps L, Addison CL. 2021. Targeting intercellular communication in the bone microenvironment to prevent disseminated tumor cell escape from dormancy and bone metastatic tumor growth. Int J of Mol Sci. Mar 13;22(6):2911. doi: 10.3390/ijms22062911.
8. Sulaiman A, McGarry S, Chambers J, Al-Kadi E, Phan A, Li L, Mediratta K, Dimitroulakos J, Addison C, Li X, Wang L. 2020. Targeting hypoxia sensitizes TNBC to cisplatin and promotes inhibition of both bulk and cancer stem cells. Int J Mol Sci. Aug 12;21(16):5788. Doi 10.3390/ijms21165788.
9. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen C, Diamandis EP, Siu KWM, Marshall JG. 2019. The plasma peptides of breast versus ovarian cancer. Clin Proteomics. Dec 23;16:43. doi: 10.1186/s12014-019-9262-0. eCollection 2019.
10. Dufresne J, Bowden P, Thavarajah T, Florentinus-Mefailoski A, Chen ZZ, Tucholska M, Norzin T, Ho MT, Phan M, Mohamed N, Ravandi A, Stanton E, Slutsky AS, Dos Santos CC, Romaschin A, Marshall JC, Addison C, Malone S, Heyland D, Scheltens P, Killestein J, Teunissen CE, Diamandis EP, Michael Siu KW, Marshall JG. 2018. The plasma peptides of ovarian cancer. Clin Proteomics. Dec 21;15:41. doi: 10.1186/s12014-018-9215-z. eCollection 2018.